49,900 Shares in Bruker Corporation $BRKR Bought by Pinnbrook Capital Management LP

Pinnbrook Capital Management LP acquired a new position in shares of Bruker Corporation (NASDAQ:BRKR) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 49,900 shares of the medical research company’s stock, valued at approximately $3,003,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Thrivent Financial for Lutherans lifted its holdings in shares of Bruker by 561.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 179,792 shares of the medical research company’s stock worth $8,470,000 after purchasing an additional 152,603 shares during the period. Hantz Financial Services Inc. increased its stake in Bruker by 202.7% in the 4th quarter. Hantz Financial Services Inc. now owns 41,306 shares of the medical research company’s stock valued at $1,946,000 after buying an additional 27,659 shares during the period. Fifth Third Bancorp raised its position in Bruker by 4,058.3% during the 1st quarter. Fifth Third Bancorp now owns 57,135 shares of the medical research company’s stock worth $2,064,000 after buying an additional 55,761 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Bruker by 317.7% in the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock worth $108,796,000 after acquiring an additional 1,756,460 shares during the period. Finally, Amundi boosted its holdings in shares of Bruker by 244.2% in the first quarter. Amundi now owns 62,611 shares of the medical research company’s stock valued at $2,261,000 after acquiring an additional 44,421 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Stock Down 0.6%

BRKR stock opened at $59.56 on Friday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The company’s 50 day simple moving average is $58.66 and its 200-day simple moving average is $47.48. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $65.30. The firm has a market capitalization of $9.07 billion, a PE ratio of -85.09, a P/E/G ratio of 1.82 and a beta of 1.28.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.11. The company had revenue of $838.50 million during the quarter, compared to the consensus estimate of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.Bruker’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts expect that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be given a $0.05 dividend. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Bruker’s dividend payout ratio (DPR) is currently -28.57%.

Wall Street Analysts Forecast Growth

BRKR has been the subject of several research analyst reports. Citigroup cut their price objective on Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research report on Wednesday, August 5th. Guggenheim raised their price objective on shares of Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Barclays boosted their price objective on shares of Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Leerink Partners increased their target price on shares of Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Finally, JPMorgan Chase & Co. boosted their price target on Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research note on Monday, June 8th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $56.64.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.